News and Trends 19 Dec 2022
Sanofi and Innate Pharma expand natural killer cell deal
Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3…
Immunotherapy
- Latest Posts
News and Trends 14 Dec 2022
ImaginAb launches trial to study neoadjuvant immunotherapy
ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated…
News and Trends 14 Dec 2022
Etcembly reveals breakthrough in optimizing TCR assets
Etcembly has announced the successful prediction and optimization of multiple T cell receptor (TCR) assets for targeting leukemias and solid…
News and Trends 12 Dec 2022
OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data
OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for…
ADVERTISEMENT
News and Trends 9 Dec 2022
Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene
This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and…
News and Trends 7 Dec 2022
Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with…
News and Trends 6 Dec 2022
Pictor receives $5M in funding for Covid antibody test and human and animal portfolios
Pictor, a global leader in immunodiagnostics, has announced a $5 million funding round to help accelerate pipeline product development projects.…
News and Trends 28 Nov 2022
Lyvgen and Bristol Myers Squibb commitment to transform cancer care
Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with…
News and Trends 28 Nov 2022
Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca
C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for…
News and Trends 22 Nov 2022
Achilles Therapeutics receives US patent for immunotherapies
A U.S. patent has been granted to Achilles Therapeutics plc for the treatment of patients with an immunotherapy, including vaccine,…
News and Trends 21 Nov 2022
FMRP – the protein behind immunotherapy resistance
Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system against their tumor. Despite success…
News and Trends 18 Nov 2022
MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma
KAHR Medical, a clinical stage biotech company that is developing a treatment for solid tumors and blood cancers has received…
News and Trends 18 Nov 2022
NW Bio reports positive top-line results from phase 3 glioblastoma trial
Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November 17) reported that both median…
News and Trends 15 Nov 2022
First patient dosed in Nouscom colorectal cancer study
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a…
News and Trends 14 Nov 2022
Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy
Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the…
More News! 8 Nov 2022
ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy
ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase…
ADVERTISEMENT
News and Trends 4 Nov 2022
Creative Medical Technology Holdings announces FDA clearance of diabetes drug
Creative Medical Technology Holdings yesterday (November 3) announced its investigational new drug (IND) application has been cleared by the U.S.…
News and Trends 31 Oct 2022
Reprogramming immune cells can fight melanoma
A new way of reprogramming immune cells to shrink or kill off cancer cells has been shown to work in…
News and Trends 26 Oct 2022
First patient dosed in trial to assess predictive performance of immuno-oncology therapy
The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to…
News and Trends 26 Oct 2022
New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies
VacV Biotherapeutics, a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its pipeline of…
